RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+21.23%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$631M
AUM Growth
+$631M
(+21%)
Cap. Flow
+$44.8M
Cap. Flow
% of AUM
7.1%
Top 10 Holdings %
Top 10 Hldgs %
26.93%
Holding
113
New
5
Increased
44
Reduced
29
Closed
9
Top Buys
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$15.5M |
| 2 |
Glaukos
GKOS
|
$10.8M |
| 3 |
Esperion Therapeutics
ESPR
|
$9.48M |
| 4 |
Biogen
BIIB
|
$8.75M |
| 5 |
ELGX
Endologix Inc
ELGX
|
$7.42M |
Top Sells
| 1 |
Teva Pharmaceuticals
TEVA
|
$13.1M |
| 2 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
$11.1M |
| 3 |
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
|
$5.44M |
| 4 |
Centene
CNC
|
$4.45M |
| 5 |
Bristol-Myers Squibb
BMY
|
$4.35M |
Sector Composition
| 1 | Healthcare | 92% |
| 2 | Financials | 1.18% |
| 3 | Technology | 0.15% |
| 4 | Energy | 0.12% |
| 5 | Consumer Staples | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $25.9M | 4.1% | 1,751,322 +1,051,322 | +150% | +$15.5M |
|
|
2
Esperion Therapeutics
ESPR
$448M
| $19.2M | 3.04% | 543,347 +268,347 | +98% | +$9.48M |
|
|
3
Biogen
BIIB
$19.4B
| $18.6M | 2.94% | 68,000 +32,000 | +89% | +$8.75M |
|
|
4
Glaukos
GKOS
$5.5B
| $16.7M | 2.65% | 325,800 +210,000 | +181% | +$10.8M |
|
5
Amgen
AMGN
$155B
| $16.4M | 2.6% | 100,000 +35,000 | +54% | +$5.74M |
|
6
Incyte
INCY
$16.5B
| $15.4M | 2.43% | 115,000 -25,000 | -18% | -$3.34M |
|
|
ABMD
7
DELISTED
Abiomed Inc
ABMD
| $14.7M | 2.32% | 117,048 +14,348 | +14% | +$1.8M |
|
8
Medtronic
MDT
$119B
| $14.6M | 2.31% | 181,115 -34,125 | -16% | -$2.75M |
|
9
Regeneron Pharmaceuticals
REGN
$61.5B
| $14.3M | 2.27% | 37,000 +10,500 | +40% | +$4.07M |
|
10
Eli Lilly
LLY
$657B
| $14.3M | 2.26% | 170,000 -45,000 | -21% | -$3.79M |
|
|
AGN
11
DELISTED
Allergan plc
AGN
| $14.1M | 2.23% | 59,000 -17,000 | -22% | -$4.06M |
|
12
Gilead Sciences
GILD
$140B
| $14.1M | 2.23% | 206,916 -52,978 | -20% | -$3.6M |
|
13
Exelixis
EXEL
$10.1B
| $13.7M | 2.16% | 630,000 -200,000 | -24% | -$4.33M |
|
|
ALXN
14
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $13.5M | 2.14% | 111,702 +20,000 | +22% | +$2.42M |
|
|
ITCI
15
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $11.6M | 1.84% | 715,664 +425,664 | +147% | +$6.92M |
|
|
ELGX
16
DELISTED
Endologix Inc
ELGX
| $11.6M | 1.83% | 1,600,000 +1,025,000 | +178% | +$7.42M |
|
|
CELG
17
DELISTED
Celgene Corp
CELG
| $11.6M | 1.83% | 93,000 | – | – |
|
18
Pfizer
PFE
$141B
| $11.5M | 1.82% | 335,422 +2,122 | +0.6% | +$72.6K |
|
19
Nektar Therapeutics
NKTR
$568M
| $11M | 1.75% | 470,000 +60,000 | +15% | +$1.41M |
|
20
BioMarin Pharmaceuticals
BMRN
$11.2B
| $11M | 1.74% | 125,000 +75,000 | +150% | +$6.58M |
|
|
21
Bristol-Myers Squibb
BMY
$96B
| $10.9M | 1.73% | 201,000 -80,000 | -28% | -$4.35M |
|
22
UnitedHealth
UNH
$281B
| $10.7M | 1.69% | 65,000 -10,017 | -13% | -$1.64M |
|
|
NVRO
23
DELISTED
NEVRO CORP.
NVRO
| $10.6M | 1.67% | 112,614 +23,300 | +26% | +$2.18M |
|
24
Vertex Pharmaceuticals
VRTX
$100B
| $10.4M | 1.65% | 95,013 +30,000 | +46% | +$3.28M |
|
25
CVS Health
CVS
$92.8B
| $10.2M | 1.62% | 130,000 -10,000 | -7% | -$785K |
|